Investors

Introduction

At Alcobra, we remain deeply committed to developing safe and effective products for the treatment of cognitive disorders including ADHD and Fragile X Syndrome and continuing to deliver value for our stockholders.

Our Investor Relations section is designed to provide you with easy access to company information.

NASDAQ: ADHD

$ 1.17

10:59 AM | Apr 24, 2017
+$0.07
(5.90%)

Day High: 1.17
Day Low:  1.11
Volume:    101,550
Delayed ~20 min., by eSignal.


Events & Presentations

Mar 28, 2017 / 8:00 AM ET